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SUMMARY
Hippo signaling has been recognized as a key tumor
suppressor pathway. Here, we perform a compre-
hensive molecular characterization of 19 Hippo
core genes in 9,125 tumor samples across 33 cancer
types using multidimensional ‘‘omic’’ data from The
Cancer Genome Atlas. We identify somatic drivers
among Hippo genes and the related microRNA
(miRNA) regulators, and using functional genomic
approaches, we experimentally characterize YAP
and TAZ mutation effects and miR-590 and miR-
200a regulation for TAZ. Hippo pathway activity is
best characterized by a YAP/TAZ transcriptional
target signature of 22 genes, which shows robust
prognostic power across cancer types. Our elastic-
net integrated modeling further reveals cancer-
type-specific pathway regulators and associated
cancer drivers. Our results highlight the importance
of Hippo signaling in squamous cell cancers, charac-
terized by frequent amplification of YAP/TAZ, high
expression heterogeneity, and significant prognostic
patterns. This study represents a systems-biology
approach to characterizing key cancer signaling
pathways in the post-genomic era.
INTRODUCTION
The Hippo signaling pathway is an evolutionarily conserved
pathway that controls organ size and cell differentiation across
diverse organisms through the regulation of cell proliferation
and apoptosis (Di Cara et al., 2015; Pan, 2010; Yu and Guan,
2013; Zhao et al., 2007). The core of the Hippo pathway is a
kinase cascade consisting of STE20-like protein kinase 1
(STK3, also known as MST2, and STK4, also known as MST1),
the large tumor suppressors (LATS1 and LATS2), and adaptor
proteins Salvador homolog 1 (SAV1) and MOB kinase activators
(MOB1A/MOB1B) (Tapon et al., 2002). These kinases directly
phosphorylate the major Hippo pathway downstream effectors,
the yes-associated protein (YAP) and the transcriptional coacti-
vator with PDZ-binding motif (TAZ), and thus inhibit the tran-
scription of their downstream target genes (Cho et al., 2006;
Hansen et al., 2015; Johnson and Halder, 2014; Oka et al.,
2008). In recent years, the critical role of the Hippo pathway in
cancer development has been increasingly recognized (Bonilla
et al., 2016; Bueno et al., 2016; Gao et al., 2014; Yu et al.,
2015; Zanconato et al., 2016). Dysregulated signaling by the Hip-
po pathway has been reported in several cancer types such as
breast, liver, lung, prostate, gastric, and colorectal tumors (Cor-
denonsi et al., 2011; Harvey et al., 2013; Jiao et al., 2014;
Lau et al., 2014; Nguyen et al., 2015; Yimlamai et al., 2014;
Zhang et al., 2017; Zhou et al., 2009). Extensive studies have
experimentally established its tumor suppressor function. For
example, STK3/STK4 loss in a mouse liver leads to uncontrolled
cell proliferation and differentiation (Zhou et al., 2009), and YAP/
TAZ overexpression leads to tissue overgrowth and cancer (Ca-
margo et al., 2007; Dong et al., 2007).
Previous studies on the Hippo pathway have focused on the
effect of its individual components in a small set of tumor con-
texts, which provides limited or biased views of this important
pathway. So far, a comprehensive molecular portrait of the
Hippo pathway in cancer has not been characterized, resulting
in important knowledge gaps for utilizing this pathway in
cancer medicine. First, given the tremendousmolecular diversity
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between cancer types, the relative importance of the Hippo
pathway in different tumor contexts remains poorly understood.
Second, because the Hippo pathway receives upstream
signaling frommultiple sources and involves many components,
it remains unclear how to effectively characterize Hippo pathway
activity as a molecular signature that can confer some clinical
utility. Third, molecular drivers and regulators that affect Hippo
pathway signaling in cancer development have not been fully
characterized. Combining the bioinformatics analysis of multidi-
mensional molecular profiling data from The Cancer Genome
Atlas (TCGA), functional perturbation approaches, and cancer-
type-specific predictive modeling, we focused on the YAP/
TAZ-centered Hippo pathway (19 core genes) and aimed to
address these critical questions in a systematic way.
RESULTS
Somatic Alteration Landscape of the Hippo Pathway
Curated from the literature, we defined 19 genes that function
mainly through the Hippo pathway as Hippo core genes (Fig-
ure 1A). Focusing on these genes, we calculated the somatic
copy number alteration (SCNA) and mutation frequency in the
pan-cancer cohort of 9,125 patients (Figure 1B; Tables S1 and
S2). The overall DNA aberration level was low, ranging from
1% to 5%. STK3 and TAZ showed the highest amplification fre-
quency, followed by TEAD4, YAP1, and STK4. Deep deletions
occurred mostly in LATS1/2, consistent with their tumor sup-
pressor role in cancer development. To identify somatic driver
candidates among Hippo genes, we identified background-cor-
rected significantly recurrent SCNAs and significantly mutated
genes (SMGs) in each cancer type using GISTIC2 (Mermel
et al., 2011) and MutSigCV (Lawrence et al., 2013), respectively
(q < 0.25; Figures 1C and 1D). For oncogenes, the most signifi-
cant amplification peak was an amplicon of 11q22.1 in cervical
squamous cell carcinoma (CESC), driven by the amplification
of YAP1 (Figure S1A). For tumor suppressors, the most signifi-
cant deletion peak was 17p in sarcoma (SARC), where TAOK1
resides (Figure S1B). Regarding the mutational profile, NF2
(23.2%) and LATS2 (9.8%) showed the highest mutation fre-
quencies in mesothelioma (MESO). NF2 showed a striking
pattern in MESO: all of the mutations were truncating mutations
and led to reduced protein expression, indicating its loss-of-
function effects (Figure S1C). These results showed that NF2
loss is a major cancer driver in silencing the Hippo pathway in
this disease (Bianchi et al., 1995; Li et al., 2014; Sekido et al.,
1995).
Several cancer types showed little somatic alterations on the
Hippo pathway compared with other cancers, such as pheo-
chromocytoma and paraganglioma (PCPG), acute myeloid leu-
kemia (LAML), and diffuse large B cell lymphoma (DLBC). To
assess the cancer types in which Hippo pathway alterations
are more (or less) prevalent than background expectation, we
employed a random sampling approach (STAR Methods). Given
the background DNA aberration frequencies in a specific cancer
type, we found that the Hippo pathway was hyper-altered in five
cancer types (top 5% among 1,000 permutations) and hypo-
altered in LAML (bottom 5%) (Figure 1E; Figure S2). Among the
hyper-altered cancer types, MESO, kidney renal papillary cell
carcinoma (KIRP), and CESC were the most significant, which
was probably due to the high frequency of NF2, LATS2, and
SAV1 mutations and YAP1 amplification. These results reveal
a highly heterogeneous somatic alternation landscape across
33 cancer types, suggesting the relative importance of Hippo
pathway dysregulation in different tumor contexts.
YAP1/TAZ Somatic Alterations and Their Functional
Effects
YAP1 and TAZ are the major downstream effectors of the Hippo
pathway. To understand the SCNA patterns of YAP1 and TAZ
across 33 cancer types, we first calculated their combined
amplification frequency, which ranged from 0% to 19%. Inter-
estingly, the top six cancer types with the highest amplification
frequency included all five squamous cell-involved cancers
(CESC, lung squamous cell carcinoma [LUSC], esophageal
squamous cell carcinoma [ESCA], head and neck squamous
cell carcinoma [HNSC], and bladder urothelial carcinoma
[BLCA]), suggesting a driving role in squamous cell cancers (Fig-
ure 2A). Next, focusing on these squamous cell cancer types, we
examined themutually exclusive pattern of YAP1 and TAZ. Inter-
estingly, the high-level amplifications of these two genes
occurred in a mutually exclusive pattern in two squamous cell
cancers (HNSC and CESC), collectively contributing to 14%
and 19% of the tumor samples (Figure 2B). The patterns suggest
functional complementarity of YAP1 and TAZ in activating down-
stream transcriptional targets.
YAP1/TAZ mutations have been rarely studied because of
their low frequencies. To understand the impact of YAP1/TAZ
somatic mutations, we experimentally assessed the effect of
each of 22 YAP1 and 19 TAZ non-silent mutations observed in
the pan-cancer cohort using moderate-throughput, sensitive
cell viability assays (Figures 2C and 2D; STAR Methods). We
transfected wild-type genes and mutants into MCF10A cells
and measured their effects. Upon overexpressing the wild-type
genes, we confirmed their stimulating effects on cell viability.
Interestingly, compared with the wild-type, we identified three
activating and three inactivating mutations in YAP1 and three
activating and two inactivating mutations in TAZ. All of the iden-
tified inactivating mutations were truncating mutations, consis-
tent with the finding that truncated proteins mainly lose their
functions. To confirm our results, we further measured the cell
numbers of selected activating and inactivating mutations,
which showed the same effects (Figures 2E and 2F). These re-
sults provide large-scale experimental evidence of YAP1/TAZ
mutation effects, highlighting an underappreciated functional di-
versity of somatic mutations observed in human cancers.
The Pan-Cancer Expression Patterns of the Hippo
Pathway
To unravel the expression pattern of Hippo pathway genes, we
first performed an analysis of mRNA expression in 15 cancer
types with a sufficient number of matched tumor and normal
samples. Among them, kidney renal clear cell carcinoma
(KIRC), kidney chromophobe (KICH), LUSC, lung adenocarci-
noma (LUAD), and thyroid cancer (THCA) had the largest
numbers of differentially expressed Hippo genes (Figure S3A).
The dysregulated pattern of individual genes varied greatly
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Figure 1. Somatic Alteration Landscape of the Hippo Pathway
(A) Diagram of 19 Hippo pathway core genes. Red depicts oncogene, and blue depicts tumor suppressor.
(B) Waterfall plots of gene mutation and copy number alteration of 19 Hippo core genes. Each row represents a gene, and each column represents a sample.
Genes are ranked from high to low somatic alteration frequency. Oncogenes are highlighted in red.
(C) Significant amplification peaks of oncogenes and deletion peaks of tumor suppressors in each cancer type identified by GISTIC2 (q < 0.25). Dot size shows
level of significance; color depicts peak status (red: amplification peak; blue: deletion peak). Oncogenes are highlighted in red.
(D) Mutation frequency heatmap of Hippo pathway core genes in each cancer type. Color depicts mutation frequency, with higher mutation frequency in a cancer
type indicated by darker color, and significantly mutated genes identified by MutSigCV (q < 0.25) are highlighted in black boxes.
(E) Hippo pathway DNA alteration load relative to the genomic background of each cancer type. The bar plots show the top percentile of the observed mutation
load in the distribution of 1,000 random sample sets with the same number and same gene length of Hippo pathway genes.
See also Figures S1 and S2 and Tables S1 and S2.
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between cancer types, and the most consistently inhibited
genes were the tumor suppressors LATS1/2 (Figure S3B). These
results reveal perturbed Hippo pathway activity in cancer
patients.
To gain a global view of Hippo gene expression across cancer
types, we next performed an unsupervised consensus clustering
of 9,125 samples of 33 cancer types based on themRNA expres-
sion data. In addition to the 19 core genes, we included another
31 genes involved in regulating Hippo pathway signaling in order
to obtain robust clustering patterns. Based on 50 Hippo-related
genes, we identified five robust clusters (Figure 3A; STAR
Methods). As expected, the samples in most cancer types
almost exclusively fell into one cluster, suggesting the domi-
nance of tissue effects (Figures 3A and 3B). Strikingly, only five
squamous cell cancers (BLCA, CESC, ESCA, HNSC, and
LUSC) were split into two clusters (clusters 1 and 3), whereas
other tumor types resided mainly in a single cluster. Thus, squa-
mous cell cancer types appear to have very distinct Hippo
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Figure 2. YAP1/TAZ Amplification and Muta-
tion Patterns
(A) The combined amplification frequency of YAP1/
TAZ in different cancer types. Squamous cell cancer
types are labeled in red.
(B) Significant mutually exclusive pattern of YAP1
and TAZ in squamous cell cancer. Each bar repre-
sents a gene, and each column is the copy number
status of a patient sample. Red depicts high-level
amplification, pink depicts low-level amplification,
light blue depicts heterozygous deletion, and dark
blue depicts homozygous deletion. p values of each
pair are shown.
(C) Functional annotation of YAP1 somatic muta-
tions based on cell viability assays. Red depicts
moderately activating, orange depicts weakly acti-
vating, yellow depicts no difference from wild-type,
and blue depicts inactivating. The relative mutation
positions are shown at the top.
(D) Functional annotation of TAZ somatic mutations.
(E) Cell images of three functional YAP1 mutants
compared with wild-type in 4 (upper row) and
11 days (lower row).
(F) Cell images of three functional TAZ mutants
compared with wild-type in 4 (upper row) and
11 days (lower row).
pathway activities that characterize the
molecular diversity of these diseases.
To determine whether the clustering
pattern of squamous cell-involved cancer
types is specific to the Hippo pathway,
we performed the same consensus clus-
tering analysis for another nine major bio-
logical pathways. We used the fraction of
the second largest cluster as an index to
quantitatively characterize the two-main-
cluster pattern of squamous cell cancers
(STAR Methods). Among all of the path-
ways surveyed, this index was significantly
higher for squamous cell-involved cancer
types than non-squamous cell cancers in the Hippo pathway
only (p = 0.005; q = 0.05; Figure 3C). These results indicate
that the high expression heterogeneity of Hippo-related genes
is unique, rather than a common property of squamous cell can-
cer types.
miRNA Regulation of Hippo Pathway Genes
To delineate microRNA (miRNA)-mediated regulation, we inte-
grated the target sequence information and co-expression
pattern of mRNA-miRNA to identify potential major regulators
for the Hippo pathway (Figure 4A). With a stringent selection
criterion, we identified a total of 69 high-confidence, recurrent
mRNA-miRNA regulatory pairs between 5 Hippo core genes
and 18 miRNAs across 9 cancer types. The most frequently
identified miRNA regulator (32 out of 69) was the miR-200 family
(hsa-miR-200a, hsa-miR-200b, hsa-miR-200c, hsa-miR-141,
and hsa-miR-429). They were predicted to regulate FRMD6,
LATS2, and TAZ. The miR-200 family is best known for its
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Figure 3. Gene Expression Pattern of Hippo Pathway Genes
(A) Unsupervised consensus clustering of Hippo component gene expression showing five distinct clusters, each marked by a different color in the top row bar.
(B) Sample distribution in the five clusters. Each row is a cancer type, and each column represents a cluster. The number in each cell shows the number of
samples classified in the corresponding cluster; red intensity shows the percentage of samples falling into one cluster.
(C) Comparison of clustering pattern of Hippo pathway with the other nine major biological pathways. y axis shows the fraction of the second largest cluster in a
given cancer type. The middle line in the box is the median, and the bottom and top of the box are the first and third quartiles, and the whiskers extend to 1.53
interquartile range of the lower quartile and the upper quartile, respectively. Only the Hippo pathway shows a statistically significant higher ratio for squamous
cell-involved cancers than for non-squamous cell cancers, indicating the uniqueness of the observed clustering pattern of Hippo pathway. Wilcoxon rank-sum
test p value and q are shown for significant comparisons.
See also Figure S3.
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Figure 4. miRNA Regulation of the Hippo Pathway
(A) High-confidence miRNA-Hippo pathway gene interaction network. miRNA-Hippo gene regulation is identified by integrating sequence information and co-
expression pattern. Significant pairs recurring in at least three cancer types are shown (q < 105 and Rs < 0.5).
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(legend continued on next page)
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regulatory role in epithelial-mesenchymal transition (EMT), and it
has been reported to inhibit YAP1 in human breast cancer (Yu
et al., 2013). In contrast, for the other Hippo major effector
TAZ, few miRNAs have been reported with strong experimental
evidence. To validate the predictedmiRNA regulators of TAZ, we
focused on miR-200a-3p and miR-590-3p, each of which con-
tains at least two perfect binding sites in the 30 UTR of TAZ (Fig-
ure 4B). Upon transfection of miR-200a-3p and miR-590-3p
mimics in two colon cancer cell lines (HCT116 and KM12), we
found that the twomiRNAs significantly suppressed TAZ expres-
sion at both mRNA and protein levels (Figures 4C–4F). Together,
these results not only present a systematic view of miRNA regu-
lators for Hippo pathway genes but also suggest that the related
miRNA analogs might be exploited clinically.
Robust Prognostic Power of a YAP/TAZ Target Gene
Signature
To assess the clinical impact of a dysregulated Hippo pathway in
cancer, we sought to examine the correlation of its activity with
patients’ overall survival times. We considered the following in-
dexes: (1) TAZ mRNA expression; (2) TAZ protein expression;
(3) YAP1 mRNA expression; (4) phosphorylated YAP protein
expression; (5) the reverse-phase protein array (RPPA)-based
Hippo pathway score (containing three protein markers); and
(6) the mRNA-based Hippo pathway score (containing 19 core
genes). In addition, because the Hippo pathway receives
upstream signaling from multiple sources and its components
undergo extensive post-transcriptional and post-translational
regulations, the expression of pathway genes may not accu-
rately capture the pathway activity. An alternative approach is
to evaluate the consequences of the Hippo pathway: the expres-
sion of the YAP/TAZ direct downstream target genes. To achieve
this, we manually curated 22 downstream target genes of the
Hippo pathway from the literature and experimental data, and
included the expression of this gene signature as another index
(Figure 5A; Figure S4; STAR Methods). Based on independent
cell line data, the selected 22 target genes showed high-level
expression changes upon YAP/TAZ perturbations and strong
positive correlations with YAP and TAZ protein expression (Fig-
ure 5A; Figure S4).
For the individual gene expressions of TAZ and YAP1, we
observed compatible patterns with their assumed functional
roles as oncogenes in multiple cancer types, but occasionally
observed the opposite patterns. For the mRNA-based Hippo
pathway score, we observed five significant but mixed correla-
tions (three versus two); for the RPPA-based Hippo pathway
score, we observed more consistent positive correlations with
patient survival in six cancer types (adrenocortical carcinoma
[ACC], glioblastoma [GBM], LUSC, KIRP, brain lower grade gli-
oma [LGG], and KIRC), consistent with the tumor suppressor
role of the pathway. The most consistent and extensive correla-
tions came from the YAP/TAZ target score based on the inte-
grated mRNA expression of their 22 target genes (Figure 5A;
STAR Methods). We found a significant negative correlation be-
tween target gene expression and overall patient survival times
in nine cancer types (Figure 5B). Indeed, the survival patterns
were quite striking in multiple cancer types (Figure 5C). Notably,
four out of the five squamous cell cancers (BLCA, LUSC, HNSC,
and CESC) showed decreased overall patient survival time with
increased YAP/TAZ transcriptional activity. In addition, the sig-
nificant survival patterns remained robust after adjusting for tu-
mor purity in the analysis: twomore cancer types, ovarian serous
cystadenocarcinoma (OV) and CESC, showed significant corre-
lations with survival time, whereas MESO lost significance
mainly because of incomplete tumor purity data. These results
indicate that the 22-gene target signature we defined represents
a robust index that can effectively capture Hippo pathway activ-
ity in cancer development, and suggest its potential utility as a
prognostic marker.
Biological Pathways and Infiltrating Immune Cell
Compositions Associated with Hippo Signaling
Given the robust prognostic power of the YAP/TAZ target score
across cancer types, we next focused on this index as a func-
tional readout of Hippo pathway activity to understand the
associated biological pathways. We first performed gene set
enrichment analysis (GSEA) (Subramanian et al., 2005) based
on the rank of mRNA expression levels in correlation with the
target score. Quite a few hallmark pathways showed consistent
correlations across all cancer types: the positively correlated
pathways included EMT, tumor necrosis factor alpha (TNF-a)
signaling, inflammatory response, angiogenesis, and more,
whereas the negatively correlated pathways included fatty
amino acid metabolism, DNA repair, MYC targets, and oxidative
phosphorylation (Figure 6A). In parallel, we examined the corre-
lations of the YAP/TAZ target score with 11 major signaling
pathway scores defined by RPPA data in 33 cancer types, and
observed highly consistent patterns (Figure S5). Cross-talk
among several pathways has been reported and discussed,
such as between the EMT pathway and nuclear factor-kB (NF-
kB) signaling (Cho et al., 2010; Lei et al., 2008; Overholtzer
et al., 2006). Therefore, it is worth looking at other networks
that may indirectly contribute to dysregulation of the Hippo
pathway in human cancers.
The Hippo pathway is primarily known for its role in cell prolif-
eration and differentiation, but emerging evidence implicates its
importance in cancer immunity (Moroishi et al., 2016; Wang
et al., 2016). To obtain an overview of the potential interactions
between Hippo pathway activity and tumor immunogenicity,
we calculated the correlations of YAP/TAZ target scores with tu-
mor-infiltrating cell abundance (inferred by TIMER), including
B cells, CD8 T cells, CD4 T cells, neutrophil, macrophage, and
dendritic cells (Li et al., 2016). We observed strong positive cor-
relations between all of these types of tumor-infiltrating cells with
YAP/TAZ activity in the vast majority of cancer types except for
testicular germ cell tumors (TGCTs) and thymomas (THYMs)
(E) Relative protein expression level of TAZ upon overexpression of miR-590-3p in HCT116 and KM12 cell lines. Western blot gel (upper panel) and quantification
(lower panel) are shown.
(F) Relative protein expression level of TAZ upon overexpression of miR-200a-3p in HCT116 and KM12 cell lines.Western blot gel (upper panel) and quantification
(lower panel) are shown.
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Figure 5. Prognostic Power of the YAP/TAZ Target Gene Signature
(A) Flow diagram of the curation of the YAP/TAZ target score. Venn diagram of shared genes from published YAP/TAZ chromatin immunoprecipitation (ChIP)-
sequencing data (Galli et al., 2015; Stein et al., 2015; Zanconato et al., 2015). Gene list was then filtered for significantly upregulated or downregulated genes
(R2-fold) in YAP/TAZ knockdown or YAP overexpression or activation transcriptomic data (Elbediwy et al., 2016; Galli et al., 2015; Kim et al., 2015; Stein et al.,
2015; Zanconato et al., 2015; Zhang et al., 2008), following selection by significant correlations with YAP and TAZ protein expression in 891 cell lines from the
Cancer Cell Line Encyclopedia (CCLE; p < 104) and manual curation leading to a 22-gene score.
(B) Summary of correlations of (1) mRNA-based 22-gene YAP/TAZ target score; (2) mRNA-based 22-gene YAP/TAZ target score after adjusting for tumor purity;
(3) YAP1mRNA; (4) YAP protein; (5) TAZ mRNA; (6) TAZ protein; (7) protein-based Hippo pathway gene score; and (8) mRNA-based Hippo pathway gene score
with patient overall survival in different cancer types. Circle size represents statistical significance; color represents direction. Overall, the YAP/TAZ target score
shows the most consistent and extensive significant correlations with patient survival times, thereby representing the best indicator for Hippo pathway activity.
(C) Kaplan-Meier survival plots of patients grouped by the YAP/TAZ target score in individual cancer types. Both p values for log rank and Cox tests are shown.
See also Figure S4.
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(Figure 6B). This pattern is concordant with previous findings that
activated YAP/TAZ signaling promotes immune cell recruitment
(Moroishi et al., 2016; Wang et al., 2016). The strong correlations
observed in this comprehensive analysis also highlight the
importance of the Hippo pathway in the tumormicroenvironment
and its potential applications in cancer immunotherapy.
Cancer-Type-Specific Hippo Pathway Regulation
Revealed by Integrative Modeling
To elucidate the key Hippo pathway components and cancer
drivers affecting or associated with the pathway activity in
various cancer types, we developed an elastic-net-based ma-
chine learning approach to build predictive models for the
YAP/TAZ target score (Figure 7; STAR Methods). For each
cancer type, we incorporated somatic mutation, SCNA,
DNA methylation, mRNA expression and RPPA-based protein
expression, and miRNA regulators, combined with cancer-
type-specific somatic drivers (e.g., SMGs and recurrent SCNAs),
and selected the top weighted features to construct a cancer-
type-specific Hippo pathway regulatory network (Figure 7A).
These networks highlight the diverse regulatory mechanisms in
different cancer types (Figure 7B; Figures S6 and S7). Among
Hippo genes, the most important regulators weremRNA expres-
sion levels of YAP1, TAZ, and TEADs. Specifically, elevated YAP/
TAZ expression levels caused by SCNAs were selected with
strong preference in our models of squamous cell-involved can-
cers (Figure 7B), supporting YAP/TAZ amplification as a driving
force in these cancer types. Decreased NF2 expression level
caused by NF2 truncating mutation was a dominant regulator
of YAP/TAZ activity in MESO. Hyper-methylation of STK3,
A
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(A) Workflow of integration modeling based on elastic net regression. For each cancer type, somatic mutation, SCNA, mRNA expression, DNA methylation, and
RPPA protein expression data of 19 Hippo core genes, and cancer-specific predicted miRNA regulators were used as features to build an elastic net regression
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(B) Hippo regulatory networks of the nine cancer types with YAP/TAZ target scores that showed significant survival correlations. Each color depicts a molecular
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See also Figures S6 and S7.
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WWC1, and TAOK2was predicted to strongly promote YAP/TAZ
amplification in colorectal cancer, MESO, and BLCA, respec-
tively. Furthermore, copy number loss for the TAOK family was
a major cause of elevated YAP/TAZ activity in KIRP and
LUSC. As for miRNA regulators, the miR-200 family was the
most frequently identified negative regulator in seven out of the
nine cancer types with a prognostic YAP/TAZ target score
(Figure 5C).
For somatic drivers associated with Hippo pathway activity,
the PTEN copy number was negatively associated with YAP/
TAZ activity in BLCA, stomach adenocarcinoma, LUSC, and
HNSC. Other recurrently identified somatic driver events
included ERBB2, RB1, and SOX2 copy number changes. Be-
sides SCNAs, IDH1 and FGFR3 mutations were predicted to
be associated with YAP/TAZ activity in LGG and BLCA, respec-
tively. Other identified associated somatic driver events included
EGFR, KRAS, and PDGFR copy number changes, consistent
with the reported functional coupling of these pathways with
Hippo pathway signaling (Chaib et al., 2017; Kapoor et al.,
2014; Lin et al., 2015; Shao et al., 2014). We note that the cancer
driver events identified may not directly affect Hippo pathway
signaling, but rather simply reflect the tumor contexts in which
the Hippo pathway tends to be perturbed; further efforts are
required to elucidate the mechanisms underlying the observed
associations. Importantly, we found that Hippo pathway activity
was associated with aberrations in a few clinically actionable
genes with Food and Drug Administration (FDA)-approved drugs
or compelling clinical evidence (Chakravarty et al., 2017), which
provides insights into clinical applications targeting the Hippo
pathway in cancer therapy.
DISCUSSION
Using the latest TCGA multi-dimensional molecular profiling
data, we performed a comprehensive molecular characteriza-
tion of the Hippo pathway across >9,000 samples of 33 cancer
types. In addition to computational analyses, we have experi-
mentally assessed the effects of YAP1/TAZ somatic mutations
using cellular assays. In total, we identified 11 non-silent
mutations that affect cell viability and proliferation, filling a crit-
ical knowledge gap about YAP1/TAZ somatic mutations. We
inferred miRNA regulation by considering both sequence
information and expression pattern, and validated two TAZ-
negative regulators, miR-200a and miR-590. This combined
computational and experimental approach represents the
direction for characterizing key cancer pathways in the post-
genome era.
Our analysis reveals that diverse mechanisms drive pathway
dysregulation in tumor contexts. We not only confirm the muta-
tion-driven mechanisms in MESO as previously reported, but
also highlight the critical role of Hippo pathway signaling in squa-
mous cell cancers. Through our integrated analyses of BLCA,
CESC, ESCA, LUSC, and HNSC, we reveal frequent YAP1/TAZ
amplifications, high expression heterogeneity, and significant
prognostic correlations. Given the strong selective pressure to
alter the Hippo pathway and activate YAP/TAZ in these cancers,
Hippo pathway signaling appears to play a major role in shaping
tumor progression and may represent a promising target for
future development of novel therapies. Another cancer of partic-
ular interest is LGG, for which Hippo pathway activity shows the
strongest correlation with patient survival times and the most
extensive associations with known drivers such as IDH1 muta-
tions. However, this disease shows low-frequency aberrations
among Hippo pathway genes in terms of both mutations and
SCNAs, suggesting a role of unknown epigenetic mechanisms
controlling Hippo pathway signaling.
Another significant contribution of this study is that we devel-
oped a YAP/TAZ transcriptional target signature of 22 genes and
demonstrated the superior performance of the expression score
based on this signature over that of individual pathway genes in
predicting patient prognosis. This represents an alternative strat-
egy for robustly inferring pathway activity: focus on the genes
affected downstream of a pathway rather than the molecular
aberrations within the pathway itself. We suspect that similar
target gene signatures can be developed for other major cancer
signaling pathways and used for pathway activity inference. The
robust prognostic power and the relatively small number of
genes involved also make this gene signature highly valuable
for potential clinical applications.
We systematically constructed cancer-type-specific Hippo
regulatory networks by integrating various types of molecular
data. The associations between somatic driver events with Hip-
po pathway signalingmay coordinate the cross-talk between the
Hippo pathway and other signaling pathways. In the modeling
results, we identified the miR-200 family as master regulators
for YAP/TAZ activity. The miR-200 family is best known for its
regulatory role in the EMT pathway. Although it has been demon-
strated that miR-200 targets YAP1 in breast cancer (Yu et al.,
2013), its functional impact on the Hippo pathway remains
largely unexplored and is worth further exploration in the future.
Taken together, our focused and systematic analyses of this
important molecular pathway will serve as a valuable resource
for understanding its dysregulation in cancers and how to maxi-
mize its clinical utility.
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Deposited Data
TCGA somatic copy number alteration
thresholded data
Genomic Data Commons https://gdc.cancer.gov/about-data/
publications/pancanatlas
TCGA somatic copy number segmentation
data by Affymetrix SNP 6 array
Genomic Data Commons and Firehose https://gdc.cancer.gov/about-data/
publications/pancanatlas
TCGA somatic mutation data Genomic Data Commons https://gdc.cancer.gov/about-data/
publications/pancanatlas
TCGA gene expression data Genomic Data Commons https://gdc.cancer.gov/about-data/
publications/pancanatlas
TCGA reverse-phase protein array (RPPA)
data
Genomic Data Commons https://gdc.cancer.gov/about-data/
publications/pancanatlas
TCGA DNA methylation data Genomic Data Commons https://gdc.cancer.gov/about-data/
publications/pancanatlas
TCGA miRNA-seq data TCGA TCGA Firehose https://gdac.broadinstitute.org
TCGA patient clinic data Genomic Data Commons https://gdc.cancer.gov/about-data/
publications/pancanatlas
Software and Algorithms
CoMET (Leiserson et al., 2015) https://bioconductor.org/packages/
release/bioc/html/coMET.html
MutSigCV (Lawrence et al., 2013) http://software.broadinstitute.org/cancer/
software/genepattern/modules/docs/
MutSigCV
GISTIC2.0 (Mermel et al., 2011) http://portals.broadinstitute.org/cgi-bin/
cancer/publications/view/216
Gene Set Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian
et al., 2005)
http://software.broadinstitute.org/gsea/
index.jsp
Experimental Models: Cell Lines
LentiX-293T cells Clontech Cat#: 632180
MCF10A ATCC ATCC CRL-10317; RRID: CVCL_0598
HCT116 MD Anderson Characterized Cell
Line Core facility
HCT116
KM12 MD Anderson Characterized Cell
Line Core facility
KM12
Chemicals, Peptides, and Recombinant Proteins
Recombinant human EGF R&D Systems Cat#: 236-EG-200
Hydrocortisone Sigma-Aldrich Cat#: H-0888
Cholera toxin Sigma-Aldrich Cat#: C-8052
Insulin Sigma-Aldrich Cat#: I-1882
MEGM Bullet Kit Lonza Cat#: CC-3150
polybrene Sigma-Aldrich Cat#: TR-1003-G
Lipofectamine RNAiMAX Transfection
Reagent
Thermo Fisher Cat#: 13778150
RPMI 1640 Corning, NY, USA Cat#:10-040-CV
Fetal bovine serum GIBCO Cat#:16140-071
DMEM with 4.5 g/L glucose, L-glutamine, &
sodium pyruvate
Corning, NY, USA Cat#:10-013-CV
(Continued on next page)
e1 Cell Reports 25, 1304–1317.e1–e5, October 30, 2018
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Han Liang
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
LentiX-293T cells (Clontech) were cultured in DMEM (with high glucose, glutamine and sodium pyruvate) with 5% fetal bovine serum
and 13 non-essential amino acid. MCF10A cells (ATCCCRL-10317) were cultured in specific growthmedium (DMEM/F12medium
with 5% HS, 20 ng/ml epidermal growth factor, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 10 mg/ml insulin, 13 Pen/strep).
Assay medium for MCF10A cells was MEBM basal medium (Lonza #CC-3151) with 100 ng/ml cholera toxin and 52 ng/ml bovine pi-
tuitary extract (Lonza #CC-4009).
HCT116 and KM12 colon carcinoma cell lines were purchased from MD Anderson Characterized Cell Line Core facility. Cell lines
were confirmed using Short TandemRepeat (STR) analysis and were tested and negative for mycoplasma contamination. Cells were
cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. MiR-590-3p and miR-200a-3p mimics, and MISSION
miRNA Negative Control 1 (HMC0002) were purchased from Sigma Aldrich. Cells were transfected with 50nM of miRNA mimics
or miRNA Negative Control using Lipofectamine RNAiMAX reagent (Thermo Fisher).
METHOD DETAILS
Somatic Copy-Number Alteration (SCNA) Analysis
We obtained TCGA thresholded SCNA scores for 9,125 patient samples from Genome Data Commons. Values equal to 2 and 2
were considered to indicate high-level amplification and homozygous deletion, respectively. Based on the copy number segmenta-
tion file, we identified significantly amplified and deleted genes (q < 0.25) in each cancer type using GISTIC2.0 with the default
parameters. We performed mutual exclusivity analysis using the CoMET module (Leiserson et al., 2015) in R for YAP1 and TAZ in
squamous-cell-involved cancers, and reported significant pairs with p < 0.05.
Somatic Mutation Analysis
We obtained somatic mutation data from Genome Data Commons (https://gdc.cancer.gov/about-data/publications/pancanatlas).
Further filtering steps were used to eliminate artifacts and prevent false-positive calls. i) Only mutations with ‘‘PASS’’ in the ‘‘FILTER’’
column were retained for all cancer types except OV and LAML, and we allowed ‘‘wga’’ for these two cancer types. ii) Hypermutated
samples with > 1,000 somatic mutations were removed, resulting in a cohort of 8,811 patient samples for downstream analyses. We
identified significantly mutated genes using MutSigCV 1.4 with a q-value cutoff of 0.25. To assess the Hippo pathway genetic alter-
ation load, we considered the tumor context and gene length by randomly selecting gene sets with similar length distributions in each
cancer type. First, we divided all protein coding genes into bins based on their gene lengths. Then, for each sampling iteration, we
randomly selected 19 genes from their corresponding bins to generate a random gene set with a similar length distribution as the
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
TAZ (V386) Antibody Cell Signaling Technology Cat#: 4883; RRID: AB_1904158
GAPDH Antibody Santa Cruz Biotechnology Cat#: sc-25778; RRID: AB_10167668
Oligonucleotides
miR-590-3p Sigma-Aldrich HMI0815
miR-200a-3p Sigma-Aldrich MIRAP00247
miRNA Negative Control I Sigma-Aldrich HMC0002
Critical Commercial Assays
CellTiter-Glo 2.0 Assay Promega Cat#: G9243
mirVanaTM miRNA Isolation Kit, with phenol Ambion Cat#: AM1561
TaqManTM Advanced miRNA cDNA
Synthesis Kit
Applied Biosystems Cat#: A28007
TaqManTM Fast Advanced Master Mix Applied Biosystems Cat#: 4444557
High-Capacity cDNA Reverse
Transcription Kit
Applied Biosystems Cat#: 4374967
RNeasy Plus Mini Kit QIAGEN Cat#: 74136
SYBRTM Select Master Mix Applied Biosystems Cat#: 4472908
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Hippo components. We calculated the frequency of somatic mutation and copy number changes of this randomly sampled gene set.
Then, by repeating the sampling 1,000 times, we calculated the rank of the observed Hippo gene DNA aberration frequency given the
random sampling background.
Functional Assays of YAP1/TAZMutations
Functions of YAP1 and TAZmutations were assayed in MCF10A cells, human non-tumorigenic mammary epithelial cells. These cells
depend on exogenous epidermal growth factor and insulin for proliferation. We hypothesized that a ‘‘driver’’ mutation confers pro-
liferation advantages to the cells in the absence of required growth factor(s), but a ‘‘passenger’’ mutation does not. The mutations,
wild-types and silent controls of YAP1 (YAP) and TAZ (WWTR1) genes were cloned into pHAGE-PURO lentivirus vector by HiTMMoB
technique as described previously(Dogruluk et al., 2015; Tsang et al., 2016). Lentivirus was generated in the LentiX-293T cells by
transfecting the pHAGE and two packaging plasmids (psPAX2 and pMD2.G). The medium of the transfected cells was refreshed
at 16 hours post-transfection. The virus was harvested at 3 days post-transfection by filtering with 0.45 mM filter and used for trans-
duction of MCF10A cells. For cell viability assay, 5,000 cells were seeded in 96-well plates in triplicate a day before transduction and
transduced by spinoculation at 906 3 g for 2 hours in the presence of polybrene (final concentration: 2.7 mg/ml). The medium was
refreshed after spinoculation with the MCF10A assay medium. Transduced cells were incubated at 37C for 2 weeks. Cell viability
of MCF10A cells was performed using CellTiter-Glo (Promega) on 4, 8, 11 and 15 days post-transduction. The functional annotations
of mutations were made based on a comparison with the corresponding wild-type clones. For cell count assays, 1,000 cells were
seeded into 24-well plates in triplicate one day before transduction. The cells were transduced and the medium was refreshed as
described above. An entire-well image of eachwell was taken by IncuCyte ZOOM systemon 4, 8, 11 and 15 days post-transduction.
Gene Expression Analysis
We obtained normalized gene expression data from Genome Data Commons (https://gdc.cancer.gov/about-data/publications/
pancanatlas). For comparison of tumor tissue to normal tissue, we used a paired t test to detect genes that were differentially ex-
pressed in tumor versus normal samples, and considered a false discovery rate (q) < 0.05 as statistically significant. All negative
valueswere considered asmissing values (NA), andwe took the log-transformed values in all downstream analyses. For cancer types
with a sufficient number of tumor–normal matched pairs (nR 10), we used the paired t test to identify expression pattern differences.
Unsupervised consensus clustering was performed on 9,125 patient samples across 33 cancer types based on the expression of
50 Hippo core or regulatory genes with less than 0.5% invalid values (NA or 0) using the Pearson distance and Ward’s method.
For each cancer type, we used theWilcoxon rank-sum test or Kruskal-Wallis nonparametric analysis of variance test to detect genes
that were differentially expressed among the cancer subtypes, and considered a false discovery rate (q) < 0.05 as statistically sig-
nificant. To compare the clustering pattern of the Hippo pathway and the other 9 major biological pathways, we used the gene
list summarized by TCGA Pancan pathway group, and performed the same clustering method. We quantified the squamous-cell-
involved separation pattern using the ratio of the second largest cluster size divided by the entire cohort sample number, and eval-
uated whether there is a statistical significant difference between squamous-cell-involved and non-squamous-cell cancers.We used
the Wilcoxon rank-sum test, considering q < 0.05 as statistically significant.
miRNA–Hippo Pathway Interaction Prediction
We obtained miRNA sequencing data from Firehose (version 2016/1/28). We used two criteria to identify the miRNA regulators for
Hippo pathway genes: i) the 30UTR of a Hippo gene should contain at least one target site matched to the seed region (position
2-8) of the miRNA; and ii) the Spearman correlation between the miRNA and the gene expression levels should be significantly nega-
tive (q < 105 and Rs < 0.5). Only interaction pairs that recurred inR 3 cancer types were considered as high-confidence miRNA–
Hippo regulators.
miRNA Target Experimental Validation
RNA Isolation and Quantitative Real-Time PCR
miRNA expression was assessed 48 h after transfection. Total RNAwas extracted using themirVanamiRNA Isolation Kit, with phenol
(Ambion) and reverse transcribed using the TaqMan Advanced miRNA cDNA Synthesis Kit (Applied Biosystems). Mature miRNAs
were detected and quantified using the TaqMan Fast Advanced Master Mix according to manufacturer’s instructions (Applied
Biosystems). TaqMan miRNA assays for hsa-miR-590-3p (Assay ID 478168_mir), hsa-miR-200a-3p (Assay ID 478490_mir), and
hsa-miR-26a-5p internal control (Assay ID 477995_mir) were purchased from Thermo Fisher. To quantify the expression of mRNA
targets, RNA was extracted using the RNeasy kit (QIAGEN) and cDNA synthesis was carried out using High-Capacity cDNA Reverse
Transcription Kit with RNase Inhibitor (Applied Biosystems). Real-time PCR was performed using SYBR Select Master Mix (Applied
Biosystems). Primer pairs (TAZ F-50-AATAGCTCAGATCCTTTCCTC-30; R-50-TCTCCTGTATCCATCTCATC-30; b-actin F-50-ATTGG
CAATGAGCGGTTC-30; R-50-CGTGGATGCCACAGGACT-30) were purchased from Sigma Aldrich. TAZmRNA level was normalized
to beta-actin and reported as fold-change compared with the negative control.
Western Blot Experiments
Total protein was isolated from cells 72 h after transfection. Cells were lysed with RIPA buffer (25 mM Tris-HCl pH 7.6, 150 mMNaCl,
1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing protease and phosphatase inhibitor cocktail (Thermo Fisher). Protein
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concentrations were determined using bicinchoninic acid assay (Pierce). Cell lysates (20ug) were resolved on 4%–20% SDS-PAGE
gels (Bio-Rad) and transferred to polyvinylidene fluoride membrane. Membranes were probed with TAZ (Cell Signaling Technology,
#4883) and GAPDH (Santa Cruz Biotechnology, sc-25778) antibodies, and visualized using a chemiluminescence western blot
detection kit (GE Healthcare). Protein levels for TAZ were quantified using ImageJ and normalized to GAPDH.
RPPA Analysis
We obtained TCGA RPPA data from The Cancer Proteome Atlas (version 4.2). Among 19 Hippo core genes, three of them had cor-
responding RPPA data. Based on the predefined role of each gene, we calculated the Hippo pathway RPPA score for each patient
using an equal-weighted summation of these three proteins: Hippo RPPA score = RPPANF2- RPPAYAP - RPPATAZ.
YAP/TAZ Target Score
We curated the 22-gene YAP/TAZ target signature (MYOF, AMOTL2, LATS2, CTGF, CYR61, ANKRD1, ASAP1, AXL, F3, IGFBP3,
CRIM1, FJX1, FOXF2, GADD45A, CCDC80, NT5E, DOCK5, PTPN14, ARHGEF17, NUAK2, TGFB2, RBMS3) using published
RNA-sequencing and ChIP-sequencing data from human cholangiocarcinoma, breast carcinoma, glioma, mesothelioma, and
normal diploid fibroblast cell lines (Galli et al., 2015; Stein et al., 2015; Zanconato et al., 2015). We considered genes to be direct
YAP/TAZ targets if their expression was robustly modulated upon YAP/TAZ knockdown (RNA-sequencing experiments) and their
transcription start site or enhancers were simultaneously YAP- and TEAD-bound (ChIP-sequencing experiments). We excluded
genes that were well-established targets of other signaling pathways (e.g., WNT, cell cycle, MAPK). We calculated the YAP/TAZ
target score within each cancer type using TCGA RNA-sequencing data (summarizing the Z-normalized log2RSEM of the expression
data for the 22 curated YAP/TAZ downstream transcription target genes). The workflow and number of genes filtered in each step is
summarized in Figure 5A.
Patient Survival Analysis
We obtained the patients’ clinical data from Genome Data Commons (https://gdc.cancer.gov/about-data/publications/
pancanatlas). We assessed the correlation between the YAP/TAZ target score and patient survival times. We used: i) the univariate
Cox proportional hazards model to assess the correlation with the patient’s overall survival time; and ii) the log-rank test to compare
patient survival curves between the groups with high- and low target score (separated by the median value), considering p < 0.05 as
statistically significant. We obtained tumor purity data from Genome Data Commons (Carter et al., 2012), and repeated the above
analysis by taking tumor purity as a Cox model covariate.
Biological Pathway and Cancer Immunity Analysis
We identified biological pathways associated with the YAP/TAZ score using the GSEA pre-ranked tool (Subramanian et al., 2005).
Briefly, each gene was ranked based on its expression correlation coefficient with the YAP/TAZ target score within each cancer
type, and the pre-ranked gene lists were then run against using GSEA Java (version 2.2.3). We reported the pathways that showed
consistent significant correlations (q < 0.05) in R 2/3 of all cancer types. We integrated the normalized protein expression data
(Z-score) from TCGA RPPA platform into 11 core cellular pathways (Akbani et al., 2014). We calculated the Spearman rank
correlations of the YAP/TAZ target score with these pathway scores, and considered q < 0.05 as statistically significant. We obtained
tumor-infiltrating immune cell abundance from TIMER (Li et al., 2016), and for each cancer type calculated Spearman rank correlation
between YAP/TAZ target score with each immune cell component score with q < 0.05 and jRsj > 0.3.
Integrative Modeling of Hippo Pathway Regulatory Networks
We obtained DNA methylation data (450k, 27k) from Genome Data Commons. For each Hippo pathway gene, we first selected the
probe with the most significant negative correlation with its mRNA expression in each cancer type. Genes with no significant corre-
lated probes were removed from this analysis. We separated the modeling of Hippo core genes with somatic driver events to prevent
potential mocking effects. First, we integrated the mutation, somatic copy number variation, gene expression, methylation, and
RPPA protein expression data of 19 Hippo core genes, and cancer-specific predicted miRNA regulators to build the elastic net
regression model. The most informative dimension of molecular data was preselected to represent the overall predictive power of
each gene for YAP/TAZ activity. This was evaluated by the Spearman correlation of the molecular data with the YAP/TAZ target
score, and the one with the strongest correlation according to its biological definition in the Hippo pathway was selected. Then,
all of the selected 19 features and miRNA regulators were pulled together and trained in elastic net regression. Second, cancer-spe-
cific significant mutated genes and copy number alterations were used separately in themodeling process. Each regression analysis
was repeated 100 times using 10-fold cross-validation. The bestmodel yielding the lowest mean squared error was used, and the top
5 weighted predictors were combined to construct a Hippo regulatory network in each cancer type.
QUANTIFICATION AND STATISTICAL ANALYSIS
All the analyses were based on 9,125 tumor samples except for miRNA (7,939), and RPPA (6,441) due to limited data availability.
Definition of significance of various statistical tests were described and referenced in their respective Method Details sections.
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DATA AND SOFTWARE AVAILABILITY
The raw data, processed data and clinical data can be found at the legacy archive of the GDC (https://portal.gdc.cancer.gov/
legacy-archive/search/f) and the PancanAtlas publication page (https://gdc.cancer.gov/about-data/publications/pancanatlas).
The mutation data can be found here (https://gdc.cancer.gov/about-data/publications/mc3-2017). TCGA data can also be explored
through the Broad Institute FireBrowse portal (http://gdac.broadinstitute.org) and the Memorial Sloan Kettering Cancer Center
cBioPortal (http://www.cbioportal.org). Details for software availability are in the Key Resources Table.
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